The impact of the Cancer Genome Atlas on lung cancer

Translational Research

Volumn 166, Issue 6, 2015, Pages 568-585

  Chang, Jeremy T H ^a   Lee, Yee Ming ^b   Huang, R Stephanie ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b University of Chicago   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGY; AUTOIMMUNE HEPATITIS; CELIAC DISEASE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; EXTRACELLULAR MATRIX; GRAFT REJECTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOST PARASITE INTERACTION; HUMAN; INDUSTRIAL HYGIENE; INFLAMMATORY BOWEL DISEASE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; TH2 CELL; THERAPY WITH HELMINTHS; TRICHURIS; BOOK; GENETICS; HUMAN GENOME; LUNG TUMOR;

ATLASES AS TOPIC; GENOME, HUMAN; HUMANS; LUNG NEOPLASMS;

EID: 84960483213     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2015.08.001     Document Type: Review

References (113)

1. Mission and Goal-TCGA. Available at: Http://cancergenome.nih.gov/abouttcga/overview/missiongoal. Accessed June 13, 2015.
2. Backgrounder-TCGA. Available at: Http://cancergenome.nih.gov/newsevents/forthemedia/backgrounder. Accessed June 13, 2015.
3. Cancers Selected for Study-TCGA. Available at: Http://cancergenome.nih.gov/cancersselected. Accessed June 13, 2015.
4. The Cancer Genome Atlas-Data Portal. Available at: Https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp. Accessed June 13, 2015.
5. The Cancer Genome Atlas (TCGA): The next stage-TCGA. Available at: Http://cancergenome.nih.gov/newsevents/newsannouncements/TCGA-The-Next-Stage. Accessed June 13, 2015.
6. WHO|Cancer. Available at: Http://www.who.int/mediacentre/factsheets/fs297/en/. Accessed June 13, 2015.
7. What is non-small cell lung cancer? Available at: Http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-what-is-non-small-cell-lung-cancer. Accessed June 13, 2015.
8. D.J. Stewart Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer Crit Rev Oncol Hematol 75 2010 173 234
9. D.J. Stewart, G. Chiritescu, S. Dahrouge, S. Banerjee, and E.M. Tomiak Chemotherapy dose-response relationships in non-small cell lung cancer and implied resistance mechanisms Cancer Treat Rev 33 2007 101 137
10. D.J. Stewart, E. Tomiak, F.M. Shamji, D.E. Maziak, and P. MacLeod Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer Lung Cancer 44 2004 241 249
11. J.G. Paez, P.A. Jänne, J.C. Lee, and et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
12. A. Antonicelli, S. Cafarotti, A. Indini, and et al. EGFR-targeted therapy for non-small cell lung cancer: Focus on EGFR oncogenic mutation Int J Med Sci 10 2013 320 330
13. B.J. Solomon, T. Mok, D.-W. Kim, and et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer N Engl J Med 371 2014 2167 2177
14. H. Yamamoto, S. Toyooka, and T. Mitsudomi Impact of EGFR mutation analysis in non-small cell lung cancer Lung Cancer 63 2009 315 321
15. K. Suda, R. Onozato, Y. Yatabe, and T. Mitsudomi EGFR T790M mutation: A double role in lung cancer cell survival? J Thorac Oncol 4 2009 1 4
16. TumorPortal. Available at: Http://www.tumorportal.org/figure/S1. Accessed June 13, 2015.
17. N. Rekhtman, P.K. Paik, M.E. Arcila, and et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: Lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations Clin Cancer Res 18 2012 1167 1176
18. Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers Nature 489 2012 519 525
19. E.A. Collisson, J.D. Campbell, A.N. Brooks, and et al. Comprehensive molecular profiling of lung adenocarcinoma Nature 511 2014 543 550
20. K. Schuster, N. Venkateswaran, A. Rabellino, L. Girard, S. Penã-Llopis, and P.P. Scaglioni Nullifying the CDKN2AB locus promotes mutant K-ras lung tumorigenesis Mol Cancer Res 12 2014 912 923
21. K. Shinjo, Y. Okamoto, B. An, and et al. Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma Carcinogenesis 33 2012 1277 1285
22. Y. Pylayeva-Gupta, E. Grabocka, and D. Bar-Sagi RAS oncogenes: Weaving a tumorigenic web Nat Rev Cancer 11 2011 761 774
23. G.H. Fisher, S.L. Wellen, D. Klimstra, and et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes Genes Dev 15 2001 3249 3262
24. L. Johnson, K. Mercer, D. Greenbaum, and et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice Nature 410 2001 1111 1116
25. W. Pao, T.Y. Wang, G.J. Riely, and et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med 2 2005 e17
26. G. Konstantinidou, G. Ramadori, F. Torti, and et al. RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas Cancer Discov 3 2013 444 457
27. Y. Zhang, Y. Xiong, and W.G. Yarbrough ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways Cell 92 1998 725 734 Available at: Http://www.ncbi.nlm.nih.gov/pubmed/9529249 Accessed May 20, 2015
28. T. Kamijo, J.D. Weber, G. Zambetti, F. Zindy, M.F. Roussel, and C.J. Sherr Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2 Proc Natl Acad Sci USA 95 1998 8292 8297
29. B. Cai, and X. Jiang Revealing biological pathways implicated in lung cancer from TCGA gene expression data using gene set enrichment analysis Cancer Inform 13 Suppl 1 2014 113 121
30. X. Li, S. Chen, T. Sun, and et al. The transcriptional regulation of SOX2 on FOXA1 gene and its application in diagnosis of human breast and lung cancers Clin Lab 60 2014 909 918 Available at: Http://www.ncbi.nlm.nih.gov/pubmed/25016694 Accessed June 13, 2015
31. V. Justilien, M.P. Walsh, S.A. Ali, E.A. Thompson, N.R. Murray, and A.P. Fields The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma Cancer Cell 25 2014 139 151
32. T. Reya, S.J. Morrison, M.F. Clarke, and I.L. Weissman Stem cells, cancer, and cancer stem cells Nature 414 2001 105 111
33. Y.-C. Chen, H.-S. Hsu, Y.-W. Chen, and et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells PLoS One 3 2008 e2637
34. A. Eramo, F. Lotti, G. Sette, and et al. Identification and expansion of the tumorigenic lung cancer stem cell population Cell Death Differ 15 2008 504 514
35. V. Justilien, R.P. Regala, I.-C. Tseng, and et al. Matrix metalloproteinase-10 is required for lung cancer stem cell maintenance, tumor initiation and metastatic potential PLoS One 7 2012 e35040
36. P. Yuan, H. Kadara, C. Behrens, and et al. Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung PLoS One 5 2010 e9112
37. R.P. Regala, E.A. Thompson, and A.P. Fields Atypical protein kinase C iota expression and aurothiomalate sensitivity in human lung cancer cells Cancer Res 68 2008 5888 5895
38. J.D. Khoury, N.M. Tannir, M.D. Williams, and et al. Landscape of DNA virus associations across human malignant cancers: Analysis of 3,775 cases using RNA-Seq J Virol 87 2013 8916 8926
39. K. Shinmura, H. Igarashi, H. Kato, and et al. CLCA2 as a novel immunohistochemical marker for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the lung Dis Markers 2014 2014 619273 Available at: Http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4274868&tool=pmcentrez&rendertype=abstract Accessed March 3, 2015
40. J. Stingl, and C. Caldas Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis Nat Rev Cancer 7 2007 791 799
41. C.R. Banerji, S. Severini, C. Caldas, and A.E. Teschendorff Intra-tumour signalling entropy determines clinical outcome in breast and lung cancer PLoS Comput Biol 11 2015 e1004115
42. X. Li, Y. Shi, Z. Yin, X. Xue, and B. Zhou An eight-miRNA signature as a potential biomarker for predicting survival in lung adenocarcinoma J Transl Med 12 2014 159
43. W. Meng, Z. Ye, R. Cui, and et al. MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma Clin Cancer Res 19 2013 5423 5433
44. R.W. Carthew, and E.J. Sontheimer Origins and mechanisms of miRNAs and siRNAs Cell 136 2009 642 655
45. O.A. Kent, and J.T. Mendell A small piece in the cancer puzzle: MicroRNAs as tumor suppressors and oncogenes Oncogene 25 2006 6188 6196
46. L. Cekaite, J.K. Rantala, J. Bruun, and et al. MiR-9,-31, and-182 deregulation promote proliferation and tumor cell survival in colon cancer Neoplasia 14 2012 868 879 Available at: Http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3459282&tool=pmcentrez&rendertype=abstract Accessed June 13, 2015
47. S. Valastyan, F. Reinhardt, N. Benaich, and et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis Cell 137 2009 1032 1046
48. S. Shin, C.A. Dimitri, S.-O. Yoon, W. Dowdle, and J. Blenis ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events Mol Cell 38 2010 114 127
49. L. Jiang, W. Zhu, K. Streicher, and et al. Increased IR-A/IR-B ratio in non-small cell lung cancers associates with lower epithelial-mesenchymal transition signature and longer survival in squamous cell lung carcinoma BMC Cancer 14 2014 131
50. T. Huang, J. Yang, and Y.-D. Cai Novel candidate key drivers in the integrative network of genes, microRNAs, methylations, and copy number variations in squamous cell lung carcinoma Biomed Res Int 2015 2015 358125
51. Q. Zhao, X. Shi, Y. Xie, J. Huang, B. Shia, and S. Ma Combining multidimensional genomic measurements for predicting cancer prognosis: Observations from TCGA Brief Bioinformatics 16 2015 291 303
52. C.W. Schindler Series introduction. JAK-STAT signaling in human disease J Clin Invest 109 2002 1133 1137
53. G. Miklossy, T.S. Hilliard, and J. Turkson Therapeutic modulators of STAT signalling for human diseases Nat Rev Drug Discov 12 2013 611 629
54. R. Abbas, K.S. McColl, A. Kresak, and et al. PIAS3 expression in squamous cell lung cancer is low and predicts overall survival Cancer Med 4 2015 325 332
55. C.D. Chung, J. Liao, B. Liu, and et al. Specific inhibition of Stat3 signal transduction by PIAS3 Science 278 1997 1803 1805 Available at: Http://www.ncbi.nlm.nih.gov/pubmed/9388184 Accessed June 13, 2015
56. A.D. Sharrocks PIAS proteins and transcriptional regulation-more than just SUMO E3 ligases? Genes Dev 20 2006 754 758
57. E.C. Brantley, L.B. Nabors, G.Y. Gillespie, and et al. Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: Implications for STAT-3 activation and gene expression Clin Cancer Res 14 2008 4694 4704
58. S.M. Dhanasekaran, O. Alejandro Balbin, G. Chen, and et al. Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes Nat Commun 5 2014 5893
59. B. Deng, Z. Sun, W. Jason, and P. Yang Increased BCAR1 predicts poor outcomes of non-small cell lung cancer in multiple-center patients Ann Surg Oncol 20 Suppl 3 2013 S701 S708
60. S. Cabodi, A. Tinnirello, B. Bisaro, and et al. p130Cas is an essential transducer element in ErbB2 transformation FASEB J 24 2010 3796 3808
61. S. Cabodi, A. Tinnirello, P. Di Stefano, and et al. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis Cancer Res 66 2006 4672 4680
62. W. Huang, B. Deng, R.-W. Wang, Q.-Y. Tan, and Y.-G. Jiang Expression of breast cancer anti-estrogen resistance 1 in relation to vascular endothelial growth factor, p53, and prognosis in esophageal squamous cell cancer Dis Esophagus 26 2013 528 537
63. W. Huang, B. Deng, R.-W. Wang, and et al. BCAR1 protein plays important roles in carcinogenesis and predicts poor prognosis in non-small-cell lung cancer PLoS One 7 2012 e36124
64. C.V. Pecot, R. Rupaimoole, D. Yang, and et al. Tumour angiogenesis regulation by the miR-200 family Nat Commun 4 2013 2427
65. M. Fallahi, A.L. Amelio, J.L. Cleveland, and R.J. Rounbehler CREB targets define the gene expression signature of malignancies having reduced levels of the tumor suppressor tristetraprolin PLoS One 9 2014 e115517
66. S.A. Brooks, and P.J. Blackshear Tristetraprolin (TTP): Interactions with mRNA and proteins, and current thoughts on mechanisms of action Biochim Biophys Acta 1829 2013 666 679
67. R.J. Rounbehler, M. Fallahi, C. Yang, and et al. Tristetraprolin impairs myc-induced lymphoma and abolishes the malignant state Cell 150 2012 563 574
68. S.E. Brennan, Y. Kuwano, N. Alkharouf, P.J. Blackshear, M. Gorospe, and G.M. Wilson The mRNA-destabilizing protein tristetraprolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis Cancer Res 69 2009 5168 5176
69. D.N. Hayes, S. Monti, G. Parmigiani, and et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts J Clin Oncol 24 2006 5079 5090
70. M.D. Wilkerson, X. Yin, V. Walter, and et al. Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation PLoS One 7 2012 e36530
71. D.W. Cescon, D. She, S. Sakashita, and et al. NRF2 pathway activation and adjuvant chemotherapy benefit in lung squamous cell carcinoma Clin Cancer Res 21 2015 2499 2505
72. S. Devarakonda, D. Morgensztern, and R. Govindan Clinical applications of the Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma Oncology (Williston Park) 27 2013 899 906 Available at: Http://www.ncbi.nlm.nih.gov/pubmed/24282988 Accessed June 13, 2015
73. I.-W. Kim, N. Han, M.G. Kim, T. Kim, and J.M. Oh Copy number variability analysis of pharmacogenes in patients with lymphoma, leukemia, hepatocellular, and lung carcinoma using the Cancer Genome Atlas data Pharmacogenet Genomics 25 2015 1 7
74. R. Redon, S. Ishikawa, K.R. Fitch, and et al. Global variation in copy number in the human genome Nature 444 2006 444 454
75. I. Johansson, and M. Ingelman-Sundberg CNVs of human genes and their implication in pharmacogenetics Cytogenet Genome Res 123 2008 195 204
76. Y. He, J.M. Hoskins, and H.L. McLeod Copy number variants in pharmacogenetic genes Trends Mol Med 17 2011 244 251
77. M.W. Wynes, T.K. Hinz, D. Gao, and et al. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies Clin Cancer Res 20 2014 3299 3309
78. J. Wrangle, W. Wang, A. Koch, and et al. Alterations of immune response of non-small cell lung cancer with azacytidine Oncotarget 4 2013 2067 2079 Available at: Http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3875770&tool=pmcentrez&rendertype=abstract Accessed May 6, 2015
79. S. Gabbara, and A.S. Bhagwat The mechanism of inhibition of DNA (cytosine-5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor Biochem J 307 Pt 1 1995 87 92 Available at: Http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1136748&tool=pmcentrez&rendertype=abstract Accessed May 24, 2015
80. C. Stresemann, and F. Lyko Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine Int J Cancer 123 2008 8 13
81. Q. Li, and M.A. Tainsky Epigenetic silencing of IRF7 and/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic viruses Katoh M, ed PLoS One 6 2011 e28683
82. O.I. Kulaeva, S. Draghici, L. Tang, J.M. Kraniak, S.J. Land, and M.A. Tainsky Epigenetic silencing of multiple interferon pathway genes after cellular immortalization Oncogene 22 2003 4118 4127
83. J. Símová, V. Polláková, M. Indrová, and et al. Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status Br J Cancer 105 2011 1533 1541
84. E. Fonsatti, H.J.M. Nicolay, L. Sigalotti, and et al. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2′-deoxycytidine in cutaneous melanoma: Immunotherapeutic implications Clin Cancer Res 13 2007 3333 3338
85. R. Claus, M. Almstedt, and M. Lübbert Epigenetic treatment of hematopoietic malignancies: In vivo targets of demethylating agents Semin Oncol 32 2005 511 520
86. A.R. Karpf, P.W. Peterson, J.T. Rawlins, and et al. Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells Proc Natl Acad Sci USA 96 1999 14007 14012 Available at: Http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=24181&tool=pmcentrez&rendertype=abstract Accessed June 13, 2015
87. M. Raghavan, N. Del Cid, S.M. Rizvi, and L.R. Peters MHC class I assembly: Out and about Trends Immunol 29 2008 436 443
88. Z. Wang, M. Gerstein, and M. Snyder RNA-Seq: A revolutionary tool for transcriptomics Nat Rev Genet 10 2009 57 63
89. A.J. Radenbaugh, S. Ma, A. Ewing, and et al. RADIA: RNA and DNA integrated analysis for somatic mutation detection PLoS One 9 2014 e111516
90. Z. Kan, B.S. Jaiswal, J. Stinson, and et al. Diverse somatic mutation patterns and pathway alterations in human cancers Nature 466 2010 869 873
91. J. Lindberg, I.G. Mills, D. Klevebring, and et al. The mitochondrial and autosomal mutation landscapes of prostate cancer Eur Urol 63 2013 702 708
92. A.V. Biankin, N. Waddell, K.S. Kassahn, and et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes Nature 491 2012 399 405
93. Y. Gui, G. Guo, Y. Huang, and et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder Nat Genet 43 2011 875 878
94. O.D. Abaan, E.C. Polley, S.R. Davis, and et al. The exomes of the NCI-60 panel: A genomic resource for cancer biology and systems pharmacology Cancer Res 73 2013 4372 4382
95. T.-H. Kim, S.Y. Lee, J.H. Rho, and et al. Mutant p53 (G199V) gains antiapoptotic function through signal transducer and activator of transcription 3 in anaplastic thyroid cancer cells Mol Cancer Res 7 2009 1645 1654
96. E.L. Kwak, Y.-J. Bang, D.R. Camidge, and et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 2010 1693 1703
97. C. Zhou, Y.-L. Wu, G. Chen, and et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 2011 735 742
98. R. Rosell, E. Carcereny, R. Gervais, and et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
99. T. Mitsudomi, S. Morita, Y. Yatabe, and et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
100. T.S. Mok, Y.-L. Wu, S. Thongprasert, and et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
101. Shaw AT, Camidge DR, Engelman JA, et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. ASCO Meet Abstract. J Clin Oncol 2012;30(15 Suppl):7508. Available at: Http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/30/15-suppl/7508. Accessed June 13, 2015.
102. R.D. Kumar, L.-W. Chang, M.J. Ellis, and R. Bose Prioritizing potentially druggable mutations with dgene: An annotation tool for cancer genome sequencing data PLoS One 8 2013 e67980
103. L.F. Stead, P. Egan, A. Devery, and et al. An integrated inspection of the somatic mutations in a lung squamous cell carcinoma using next-generation sequencing PLoS One 8 2013 e78823
104. R.S. Herbst, D.R. Gandara, F.R. Hirsch, and et al. Lung master protocol (lung-MAP)- A biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400 Clin Cancer Res 21 2015 1514 1524
105. P.K. Kimes, C.R. Cabanski, M.D. Wilkerson, and et al. SigFuge: Single gene clustering of RNA-seq reveals differential isoform usage among cancer samples Nucleic Acids Res 42 2014 e113
106. M. Sultan, M.H. Schulz, H. Richard, and et al. A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome Science 321 2008 956 960
107. D. Ramsköld, E.T. Wang, C.B. Burge, and R. Sandberg An abundance of ubiquitously expressed genes revealed by tissue transcriptome sequence data PLoS Comput Biol 5 2009 e1000598
108. C.A. Maher, C. Kumar-Sinha, X. Cao, and et al. Transcriptome sequencing to detect gene fusions in cancer Nature 458 2009 97 101
109. N.A. Faustino, and T.A. Cooper Pre-mRNA splicing and human disease Genes Dev 17 2003 419 437
110. J.P. Venables Aberrant and alternative splicing in cancer Cancer Res 64 2004 7647 7654
111. Y. Dong, A. Kaushal, M. Brattsand, J. Nicklin, and J.A. Clements Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers Clin Cancer Res 9 2003 1710 1720 Available at: Http://www.ncbi.nlm.nih.gov/pubmed/12738725 Accessed June 13, 2015
112. Y. Dong, L.T. Bui, D.M. Odorico, and et al. Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: Nuclear, cytoplasmic and secreted forms Endocr Relat Cancer 12 2005 875 889
113. C. Planque, Y.-H. Choi, S. Guyetant, N. Heuzé-Vourc'h, L. Briollais, and Y. Courty Alternative splicing variant of kallikrein-related peptidase 8 as an independent predictor of unfavorable prognosis in lung cancer Clin Chem 56 2010 987 997